3-(9-anthryl)-D,L-alanine | 135092-49-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 3-(9-anthryl)-D,L-alanine
• 英文别名: 3-(9-Anthryl)-L-alanine；(2S)-2-amino-3-anthracen-9-ylpropanoic acid
• CAS: 135092-49-8
• 化学式: C₁₇H₁₅NO₂
• 分子量: 265.312
• InChiKey: MRVJUNXMEDRMRO-INIZCTEOSA-N

物化性质

• 沸点：
  503.4±38.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] CYSTEINE ARYLATION DIRECTED BY A GENETICALLY ENCODABLE π-CLAMP<br/>[FR] ARYLATION DE CYSTÉINE DIRIGÉE PAR UN N-CLAMP ENCODABLE GÉNÉTIQUEMENT
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2015175941A1

  公开（公告）日：2015-11-19

  Disclosed are methods of single-site-specific cysteine modification on peptide/protein molecules under physiologically relevant conditions. This process features several significant advantages over existing methods of peptide modification, such as specificity towards thiols over other nucleophiles (e.g., amines, hydroxyls), excellent functional group tolerance, and mild reaction conditions. Especially important is the specificity observed for thiols appearing in an X-Cys-Pro-X sequence over other thiols or disulfides, where X is Phe, Trp, or Tyr; under the inventive conditions, other cysteines or reactive functional groups on the same peptide/protein chain are not functionalized.

  披露了在生理条件下对肽/蛋白分子进行单位点特异性半胱氨酸修饰的方法。该过程具有几个显著优点，相比现有的肽修饰方法，如对硫醇具有特异性而不影响其他亲核试剂（如胺基、羟基）、良好的官能团容忍性和温和的反应条件。尤其重要的是，观察到对出现在X-Cys-Pro-X序列中的硫醇的特异性，而不影响其他硫醇或二硫键，其中X为Phe、Trp或Tyr；在创新的条件下，同一肽/蛋白链上的其他半胱氨酸或反应性官能团不会发生功能化。
• [EN] NOVEL COMPOUNDS WITH DUAL ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS À DOUBLE ACTIVITÉ
  申请人：YISSUM RES DEV CO

  公开号：WO2017042805A1

  公开（公告）日：2017-03-16

  The invention generally relate to novel compounds and uses thereof in preventing antifouling by unicellular organisms and in attracting cells from multicellular organisms.

  这项发明通常涉及新化合物及其在防止单细胞生物的污垢和吸引多细胞生物细胞方面的用途。
• Highly homogeneous molecular markers for electrophoresis
  申请人：Invitrogen Corporation

  公开号：US20040014082A1

  公开（公告）日：2004-01-22

  The invention relates to marker molecules for identifying physical properties of molecular species separated by the use of electrophoretic systems. The invention further relates to methods for preparing and using marker molecules.

  这项发明涉及用于识别电泳系统分离的分子物种的物理性质的标记分子。该发明还涉及制备和使用标记分子的方法。
• PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF
  申请人：Cai Sui Xiong

  公开号：US20080300191A1

  公开（公告）日：2008-12-04

  Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing or reducing the replication of coronavirus, or picornaviruses, with the compounds of the present invention

  本申请公开了用于冠状病毒和SARS-CoV，或小RNA病毒的蛋白酶抑制剂，以及利用这些蛋白酶抑制剂预防、减少、改善和治疗由冠状病毒和SARS-CoV，或小RNA病毒引起的疾病或症状的用途。还公开了使用本发明的化合物减少或预防冠状病毒，或小RNA病毒的传播，并预防或减少冠状病毒，或小RNA病毒的复制的方法。
• [EN] BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS<br/>[FR] COMPOSÉS DIACYLHYDRAZINE CONTENANT DU BORE
  申请人：INTREXON CORP

  公开号：WO2016044390A1

  公开（公告）日：2016-03-24

  The present disclosure provides boron-containing diacylhydrazines having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供具有式（I）的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物，其中A、R4和R5如规范中所述。本公开还提供了含硼二酰肼化合物在蜕皮激素受体基础上的诱导基因表达系统的用途。因此，本公开适用于基因治疗、疾病治疗、大规模蛋白质和抗体生产、基于细胞的筛选分析、功能基因组学、蛋白质组学、代谢组学和调节转基因生物的特征等应用中，其中对基因表达水平的控制是可取的。